The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review

The lack of success in prostate cancer from immune checkpoint inhibitors, which is likely multifactorial, has led to the development and investigation of a number of other novel immunotherapeutic techniques, including antibody–drug conjugates, T-cell redirected bispecific therapies, cancer vaccines...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Felicity C., Dorff, Tanya B., Tran, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Advancing and Innovating in the Era of PSMA theranostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155011/
https://www.ncbi.nlm.nih.gov/pubmed/37152424
http://dx.doi.org/10.1177/17588359231170474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155011/
https://www.ncbi.nlm.nih.gov/pubmed/37152424
http://dx.doi.org/10.1177/17588359231170474

Ejemplares similares